SCHEMBL1747722

SCHEMBL1747722

CC(=O)N1Cc2ccccc2C2(CCN(C3(C)CCCCC3)CC2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.43
HSD11B1 P28845 3/20 0.41
CYP3A4 P08684 3/20 0.38
HIF1A Q16665 2/20 0.38
OPRM1 P35372 2/20 0.38
CYP2C19 P33261 2/20 0.38
OPRL1 P41146 1/20 0.38
KCNH2 Q12809 1/20 0.38
CCR5 P51681 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
CYP2D6 P10635 2/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747728 0.85 CTSB (0.41) NOTUMHSD11B1CYP3A4HIF1AOPRM1
SCHEMBL12935358 0.84 NOTUM (0.40) NOTUMHSD11B1CYP3A4HIF1AOPRM1
SCHEMBL22765655 0.83 NOTUM (0.58) NOTUMHSD11B1CYP3A4OPRM1CYP2C19
SCHEMBL1747817 0.81 NOTUM (0.49) NOTUMHSD11B1CYP3A4HIF1AOPRM1
SCHEMBL12935300 0.80 KCNH2 (0.50) NOTUMOPRM1OPRL1KCNH2OPRK1
SCHEMBL12935220 0.80 KCNH2 (0.50) NOTUMOPRM1OPRL1KCNH2OPRK1
SCHEMBL11939137 0.79 NOTUM (0.43) NOTUMHSD11B1OPRM1OPRL1KCNH2
SCHEMBL12934775 0.78 OPRM1 (0.46) NOTUMHSD11B1CYP3A4OPRM1OPRL1
SCHEMBL12934733 0.77 SIGMAR1 (0.61) OPRM1OPRL1KCNH2OPRK1SIGMAR1
SCHEMBL7568469 0.77 NOTUM (0.50) NOTUMHSD11B1OPRM1CYP2C19OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817036-B1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2012-07-04 EP disclosed
US-7863449-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-04 US disclosed
US-7863449-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-04 US disclosed
US-7863449-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-04 US disclosed
EP-1817036-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 EP disclosed
US-20060270653-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-11-30 US disclosed
WO-2006058303-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270653-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 NOTUM 1391/4885HSD11B1 1412/4885CYP3A4 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.